Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Zeneca Support Of Nolvadex Risk Claim Includes Lawsuit Against Lilly Evista

  • News

Executive Summary

Zeneca's expanded support for Nolvadex' breast cancer risk reduction claim includes a lawsuit to prevent Lilly from off-label promotion of its drug Evista for the same indication.

You may also be interested in...



Lilly Must Design New Sales Rep Training Under Evista Preliminary Injunction

Lilly must create a new training program for its sales representatives which instructs them not to promote Evista for reduction in risk of breast cancer under a federal court preliminary injunction.

Lilly Must Design New Sales Rep Training Under Evista Preliminary Injunction

Lilly must create a new training program for its sales representatives which instructs them not to promote Evista for reduction in risk of breast cancer under a federal court preliminary injunction.

Barr

Authorized generic tamoxifen (Zeneca's Nolvadex) distributor files a motion to become a plaintiff-intervenor in Zeneca's federal lawsuit against Lilly alleging false and misleading promotion of Evista (raloxifene) for breast cancer. A hearing for the case is schedule for May 17 (1"The Pink Sheet" March 1, p. 27)

Table

View full table

Tags:
UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By